EAM
SRPT icon

Eagle Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Eagle Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$45.2M Sell
371,435
-34,611
-9% -$4.78M 0.23% 121
2024
Q2 		$63.6M Buy
406,046
+192,617
+90% +$24.7M 0.34% 105
2024
Q1 		$27.4M Sell
213,429
-2,739
-1% -$336K 0.14% 155
2023
Q4 		$20.8M Sell
216,168
-2,054
-0.9% -$197K 0.11% 185
2023
Q3 		$26.5M Buy
218,222
+341
+0.2% +$38.5K 0.16% 152
2023
Q2 		$25M Sell
217,881
-3,334
-2% -$430K 0.14% 160
2023
Q1 		$30.5M Buy
+221,215
New +$28.7M 0.18% 140
2021
Q1 		– Sell
-316,248
Closed -$53.9M – 666
2020
Q4 		$53.9M Sell
316,248
-25,629
-7% -$3.8M 0.3% 112
2020
Q3 		$48.3M Sell
341,877
-100,115
-23% -$15.2M 0.25% 145
2020
Q2 		$71.9M Buy
441,992
+1,582
+0.4% +$215K 0.41% 99
2020
Q1 		$43.1M Sell
440,410
-3,041
-0.7% -$348K 0.27% 142
2019
Q4 		$57.2M Buy
443,451
+8,151
+2% +$823K 0.27% 145
2019
Q3 		$32.8M Sell
435,300
-286,588
-40% -$33.8M 0.17% 191
2019
Q2 		$110M Sell
721,888
-191,634
-21% -$23.3M 0.56% 43
2019
Q1 		$109M Sell
913,522
-175,034
-16% -$22.5M 0.58% 36
2018
Q4 		$119M Buy
1,088,556
+21,238
+2% +$2.66M 0.75% 14
2018
Q3 		$172M Buy
1,067,318
+379,162
+55% +$51.8M 0.83% 8
2018
Q2 		$91M Sell
688,156
-291,385
-30% -$27.5M 0.49% 58
2018
Q1 		$72.6M Sell
979,541
-7,242
-0.7% -$483K 0.39% 84
2017
Q4 		$55.2M Sell
986,783
-19,439
-2% -$1.03M 0.3% 113
2017
Q3 		$49.9M Buy
1,006,222
+207,810
+26% +$8.31M 0.29% 125
2017
Q2 		$26.9M Buy
798,412
+200,103
+33% +$6.52M 0.16% 209
2017
Q1 		$17.7M Buy
598,309
+6,137
+1% +$190K 0.11% 253
2016
Q4 		$16.2M Sell
592,172
-1,283
-0.2% -$51.5K 0.11% 259
2016
Q3 		$36.4M Buy
593,455
+239,165
+68% +$7.23M 0.25% 126
2016
Q2 		$6.76M Buy
+354,290
New +$6.56M 0.05% 369

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Eagle Asset Management's SRPT Position: Q3 2024 in Review

Eagle Asset Management reduced its Sarepta Therapeutics (SRPT) stake by 8.5% in Q3 2024, selling an estimated $4.78M and leaving 371,435 shares worth $45.2M. The position accounts for 0.23% of the portfolio, ranked #121.

Eagle Asset Management first reported a position in SRPT in Q2 2016 and has held it in 26 quarters since. The position peaked at $172M in Q3 2018. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Eagle Asset Management held 371,435 shares of Sarepta Therapeutics worth $45.2M as of Q3 2024.
  • Eagle Asset Management sold 34,611 Sarepta Therapeutics shares in Q3 2024, an estimated $4.78M.
  • Sarepta Therapeutics made up 0.23% of Eagle Asset Management's portfolio in Q3 2024, its #121 holding.
  • Eagle Asset Management first reported a position in Sarepta Therapeutics in Q2 2016 and has held it in 26 quarters since.
  • Eagle Asset Management's Sarepta Therapeutics position peaked at $172M in Q3 2018.
  • 457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.